Discussions of autoimmune thyroid disease often focus on inherited susceptibility and immune responses. A 2026 Nature paper by Nicola and colleagues adds another perspective: B cells infiltrating the thyroid may acquire DNA changes after birth, with these cell populations undergoing local selection.
Research question
Somatic mutations are DNA changes acquired by a subset of cells, distinct from inherited genetic variation. Expansion of a mutated cell produces a population sharing that mutation—a clone. This study asked which mutations are repeatedly selected in the chronically inflamed thyroid.
Methods and main findings
The investigators studied thyroid tissue from nine patients with Hashimoto’s thyroiditis and five with Graves’ disease. They combined NanoSeq, a high-accuracy method for detecting rare mutations, with single-nucleus DNA analysis and spatial analyses.
Thyroid B cells contained many independent cell populations with loss-of-function mutations in TNFRSF14 (HVEM) or CD274 (PD-L1), genes involved in immune regulation. Mutations in these genes were detected in 10 and 11 of the 14 patients, respectively. Rather than one dominant clone, many small clones were present. Antibodies derived from some clones reacted with TPO or TG. Original article
What the findings mean
Repeated mutations affecting the same pathways in independent cell populations are difficult to explain solely as random events. The authors suggest that changes in immune regulation may favor cell persistence or expansion in the local environment.
This perspective shifts attention from autoimmunity as a fixed predisposition to the changing composition of cell populations within a persistently inflamed organ. It also illustrates why detecting mutations in small populations requires greater sensitivity than conventional analyses may provide.
Limitations
The study included 14 patients and did not fully distinguish mutations that initiate disease from those selected during inflammation. The Graves’ disease cases were selected for high anti-TPO antibody levels or extensive intrathyroidal lymphocyte infiltration. Generalization to all patients with Graves’ disease therefore requires caution.
Finding mutations in immune checkpoint genes does not mean that existing checkpoint inhibitors can treat thyroid autoimmunity. Which cells and functions should be altered, and in which direction, remain separate questions.
Journal Club perspective
Future work should examine interactions between mutated B cells and surrounding T cells, and test whether targeting particular mutations or cell populations changes inflammation. Whether small tissue clones can be tracked in blood is another question relevant to clinical translation. The study’s distinctive contribution is to introduce a temporal dimension: local cell populations evolve during autoimmune disease.
References
Nicola PA, Lawson ARJ, Tidd A, et al. Polyclonal selection of immune checkpoint mutations in thyroid autoimmunity. Nature. 2026;654:131–141. DOI: https://doi.org/10.1038/s41586-026-10493-9
